Cladis Investment Advisory’s AbbVie ABBV Stock Holding History

Cladis Investment Advisory’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$396K	Buy	1,573 +15	+1%	+$3.23K	0.19%	116
2026 Q1	$339K	Hold	1,558	–	–	0.19%	116
2025 Q4	$356K	Hold	1,558	–	–	0.19%	110
2025 Q3	$361K	Hold	1,558	–	–	0.21%	110
2025 Q2	$289K	Hold	1,558	–	–	0.18%	115
2025 Q1	$326K	Hold	1,558	–	–	0.24%	99
2024 Q4	$277K	Sell	1,558 -277	-15%	-$50.9K	0.2%	103
2024 Q3	$362K	Hold	1,835	–	–	0.25%	94
2024 Q2	$315K	Hold	1,835	–	–	0.23%	103
2024 Q1	$334K	Hold	1,835	–	–	0.25%	102
2023 Q4	$284K	Hold	1,835	–	–	0.22%	105
2023 Q3	$274K	Hold	1,835	–	–	0.24%	98
2023 Q2	$247K	Hold	1,835	–	–	0.21%	111
2023 Q1	$292K	Buy	1,835 +130	+8%	+$19.9K	0.26%	102
2022 Q4	$276K	Hold	1,705	–	–	0.27%	104
2022 Q3	$229K	Buy	1,705 +230	+16%	+$33K	0.25%	109
2022 Q2	$226K	Buy	1,475 +150	+11%	+$22.9K	0.23%	115
2022 Q1	$215K	Buy	+1,325	New	+$192K	0.17%	136

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Cladis Investment Advisory's ABBV Position: Q2 2026 in Review

Cladis Investment Advisory increased its AbbVie (ABBV) stake by 0.96% in Q2 2026, buying an estimated $3.23K and bringing the position to 1,573 shares worth $396K. The position accounts for 0.19% of the portfolio, ranked #116.

Cladis Investment Advisory first reported a position in ABBV in Q1 2022 and has held it in 18 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Cladis Investment Advisory held 1,573 shares of AbbVie worth $396K as of Q2 2026.
Cladis Investment Advisory bought 15 AbbVie shares in Q2 2026, an estimated $3.23K.
AbbVie made up 0.19% of Cladis Investment Advisory's portfolio in Q2 2026, its #116 holding.
Cladis Investment Advisory first reported a position in AbbVie in Q1 2022 and has held it in 18 quarters since.
4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Cladis Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.